teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 59
teleo-codex/entities/health/arpa-h-evident.md
Teleo Agents ad6548b723
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
Details
vida: extract claims from 2026-04-24-arpa-h-evident-139m-behavioral-health-psychedelics 
- Source: inbox/queue/2026-04-24-arpa-h-evident-139m-behavioral-health-psychedelics.md
- Domain: health
- Claims: 0, Entities: 4
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
2026-05-11 04:28:15 +00:00

3.1 KiB
Raw Blame History

ARPA-H EVIDENT Initiative

Full name: Evidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health (EVIDENT)

Parent organization: Advanced Research Projects Agency for Health (ARPA-H)

Total funding: Up to $139.4 million

Launch date: April 24, 2026

Mission: Generate FDA-ready clinical endpoints for rapid-acting behavioral health therapies across three modalities: digital interventions, neuromodulation, and neuroplastogens (including psychedelics).

Program Structure

Psychedelic research component:

  • Minimum $50M allocated to match qualifying state government investments in psychedelic research for serious mental illness populations
  • Implements federal matching mechanism from Trump April 18, 2026 Executive Order on psychedelics
  • Texas IMPACT consortium: $50M state + $50M ARPA-H federal match = ~$100M total for ibogaine research

Selected research teams:

  • INVI MindHealth (Denver): Real-time biomarker platform for neuromodulation + psychedelic therapies
  • Diamond Therapeutics (Toronto): Contributing Phase 2a psilocybin data for generalized anxiety disorder (GAD)
  • University of Wisconsin: Contributing data from 3 approved psilocybin trials

Award structure: Rolling basis announcements for future teams

Strategic Context

ARPA-H vs. NIH distinction: ARPA-H operates on DARPA-like model—time-limited, mission-driven, risk-tolerant. Unlike NIH RO1 grants, ARPA-H funds teams to produce specific regulatory-ready endpoints rather than open-ended research.

Regulatory pathway: EVIDENT produces clinical evidence → FDA approval → CMS coverage review → reimbursement. Initiative only accelerates first step (evidence generation), not subsequent access barriers.

Timeline

  • 2026-04-18 — Trump Executive Order directs ARPA-H to match state psychedelic research investments
  • 2026-04-24 — ARPA-H announces EVIDENT initiative with $139.4M total funding, including $50M+ psychedelic research matching component
  • 2026-04-24 — First research teams announced: INVI MindHealth, Diamond Therapeutics, University of Wisconsin
  • 2026-04-24 — Texas IMPACT consortium $100M ibogaine research funding confirmed ($50M state + $50M federal match)

Analysis

EVIDENT represents the first systematic federal investment vehicle for psychedelic-assisted therapy research, transitioning funding from private pharmaceutical companies (Compass, Usona) and philanthropy (MAPS) to government-backed infrastructure. The $139.4M allocation is modest by NIH standards but leveraged through ARPA-H's mandate to produce FDA-ready endpoints rather than general research outputs.

Notably, the initiative incorporates international data (Diamond Therapeutics, Canadian company) into US regulatory pathways, demonstrating cross-border evidence integration. The GAD indication for Diamond's psilocybin trial addresses a larger population (~40M US sufferers) than treatment-resistant depression or PTSD.

Critical gap: EVIDENT focuses exclusively on evidence generation without addressing reimbursement, workforce training, or care delivery infrastructure—the binding constraints on patient access post-approval.